John C.M. Farquhar Sells 22,562 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $28.31, for a total transaction of $638,730.22. Following the completion of the transaction, the chief executive officer directly owned 436,280 shares of the company’s stock, valued at $12,351,086.80. The trade was a 4.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Friday, July 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.75, for a total transaction of $626,095.50.
• On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00.
• On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $28.50, for a total transaction of $643,017.00.

Heartflow Price Performance

Shares of HTFL stock opened at $31.01 on Friday. The firm has a market capitalization of $2.67 billion and a price-to-earnings ratio of -9.97. The business has a fifty day moving average of $28.80 and a 200 day moving average of $27.70. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $41.22.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15. The firm had revenue of $64.08 million for the quarter. The company’s quarterly revenue was up 47.7% on a year-over-year basis. As a group, equities research analysts expect that Heartflow, Inc. will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Heartflow

Several institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new stake in Heartflow during the fourth quarter worth $27,000. Russell Investments Group Ltd. purchased a new position in Heartflow in the fourth quarter valued at $45,000. Legal & General Group Plc acquired a new position in shares of Heartflow in the third quarter worth about $59,000. Essential Partners LLC acquired a new stake in shares of Heartflow during the 1st quarter valued at about $57,000. Finally, Strs Ohio acquired a new stake in shares of Heartflow during the 4th quarter valued at about $99,000.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Piper Sandler restated an “overweight” rating on shares of Heartflow in a research note on Thursday, June 11th. Wells Fargo & Company increased their price objective on shares of Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. William Blair started coverage on shares of Heartflow in a research report on Monday, May 4th. They set an “outperform” rating for the company. Robert W. Baird began coverage on shares of Heartflow in a report on Friday, July 31st. They issued an “outperform” rating and a $34.00 price target on the stock. Finally, Weiss Ratings upgraded Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.57.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.